Literature DB >> 8251321

Successful treatment with hydrochlorothiazide and amiloride in an infant with congenital nephrogenic diabetes insipidus.

T M Uyeki1, F L Barry, S M Rosenthal, R S Mathias.   

Abstract

We report a 9-month-old male Latino infant with congenital nephrogenic diabetes insipidus (NDI) who presented with hypernatremic dehydration aggravated by severe gastroenteritis. Initially, the infant was managed with intravenous fluids followed by standard 20 cal/ounce formula and pharmacological therapy, resulting in normalization of his serum sodium level. While hydrochlorothiazide therapy alone or in combination with prostaglandin inhibitors or amiloride has been successful in children and adolescents, this is the first report of the successful use of hydrochlorothiazide and amiloride in an infant with congenital NDI.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8251321     DOI: 10.1007/bf00852546

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  17 in total

1.  Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothiazide in the treatment of nephrogenic diabetes insipidus.

Authors:  N Knoers; L A Monnens
Journal:  J Pediatr       Date:  1990-09       Impact factor: 4.406

2.  Thiazide-sensitive sodium chloride cotransport in early distal tubule.

Authors:  D H Ellison; H Velázquez; F S Wright
Journal:  Am J Physiol       Date:  1987-09

3.  Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus.

Authors:  U Alon; J C Chan
Journal:  Am J Nephrol       Date:  1985       Impact factor: 3.754

4.  Nephrogenic diabetes insipidus and intracerebral calcification.

Authors:  O Schofer; R Beetz; K Kruse; C Rascher; C Schütz; J Bohl
Journal:  Arch Dis Child       Date:  1990-08       Impact factor: 3.791

5.  Nephrogenic diabetes insipidus: close linkage with markers from the distal long arm of the human X chromosome.

Authors:  N Knoers; H van der Heyden; B A van Oost; H H Ropers; L Monnens; J Willems
Journal:  Hum Genet       Date:  1988-09       Impact factor: 4.132

6.  Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus.

Authors:  S J Lolait; A M O'Carroll; O W McBride; M Konig; A Morel; M J Brownstein
Journal:  Nature       Date:  1992-05-28       Impact factor: 49.962

7.  Congenital nephrogenic diabetes insipidus-vasopressin and prostaglandins in response to treatment with hydrochlorothiazide and indomethacin.

Authors:  W Rascher; W Rosendahl; I A Henrichs; R Maier; H W Seyberth
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

8.  Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus.

Authors:  Y Pan; A Metzenberg; S Das; B Jing; J Gitschier
Journal:  Nat Genet       Date:  1992-10       Impact factor: 38.330

Review 9.  Integrated actions of renal medullary prostaglandins in the control of water excretion.

Authors:  J B Stokes
Journal:  Am J Physiol       Date:  1981-06

10.  Hypokalaemia and diuretics: an analysis of publications.

Authors:  D B Morgan; C Davidson
Journal:  Br Med J       Date:  1980-03-29
View more
  4 in total

Review 1.  Diabetes insipidus.

Authors:  P H Baylis; T Cheetham
Journal:  Arch Dis Child       Date:  1998-07       Impact factor: 3.791

Review 2.  Diabetes insipidus in children: pathophysiology, diagnosis and management.

Authors:  Tim Cheetham; Peter H Baylis
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Treatment of nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride.

Authors:  V Kirchlechner; D Y Koller; R Seidl; F Waldhauser
Journal:  Arch Dis Child       Date:  1999-06       Impact factor: 3.791

4.  EGF Receptor Inhibition by Erlotinib Increases Aquaporin 2-Mediated Renal Water Reabsorption.

Authors:  Pui W Cheung; Naohiro Nomura; Anil V Nair; Nutthapoom Pathomthongtaweechai; Lars Ueberdiek; Hua A Jenny Lu; Dennis Brown; Richard Bouley
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.